An Observational, Retrospective Cohort Database Study to Assess the Safety of Boostrix (U.S. Formulation), a Reduced Tetanus, Diphtheria, Acellular Pertussis Vaccine (Tdap), Following Routine Immunization of Pregnant Women in the United States
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 08 May 2019 Planned number of patients changed from 15000 to 30000.
- 08 May 2019 Planned End Date changed from 30 Apr 2020 to 30 Aug 2020.
- 08 May 2019 Planned primary completion date changed from 30 Apr 2020 to 30 Aug 2020.